A hyperosmolar oxygen yielding blood substitute for cardiopulmonary bypass

T. M. Runge, J. W. McGinity, S. E. Frisbee, Y. M. Laurel, J. H. Calhoon, J. R. Ybarra, S. E. Ottmers, J. C. Briceno

Research output: Contribution to journalConference article

3 Scopus citations

Abstract

Conventional cardiopulmonary bypass (CPB) is associated with progressive anasarca and hypoxic acidosis. The former is reduced by hetastarch, mannitol, furosemide, albumin and blood. Thirty six large nubian cross ungulates were subjected to CPB to test their capacity to act as oxygen yielding blood substitutes capable of reducing anasarca. A hyperosmolar oxygen-yielding blood substitute is feasible for CPB to enhance brain oxygenation and diminish anasarca. It decreases anasarca more than normo-osmolar crystalloid prime combined with hetastarch, mannitol, and furosemide. A large portion of the perfluorocarbon can be retrieved post-operatively.

Original languageEnglish (US)
Pages (from-to)A154
JournalArtificial Cells, Blood Substitutes, and Immobilization Biotechnology
Volume22
Issue number5
StatePublished - Nov 1 1994
EventProceedings of the 11th Congress of the International Society for Artificial Cells, Blood Substitutes and Immobilization Biotechnology, (ISABI) - Boston, MA, USA
Duration: Jul 24 1994Jul 27 1994

ASJC Scopus subject areas

  • Biotechnology
  • Biomedical Engineering

Fingerprint Dive into the research topics of 'A hyperosmolar oxygen yielding blood substitute for cardiopulmonary bypass'. Together they form a unique fingerprint.

  • Cite this

    Runge, T. M., McGinity, J. W., Frisbee, S. E., Laurel, Y. M., Calhoon, J. H., Ybarra, J. R., Ottmers, S. E., & Briceno, J. C. (1994). A hyperosmolar oxygen yielding blood substitute for cardiopulmonary bypass. Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, 22(5), A154.